Moderate hypofractionated boost to the prostate with pelvic RT (external beam radiotherapy) for Prostate Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Princess Margaret Cancer Center, Toronto, CanadaProstate CancerModerate hypofractionated boost to the prostate with pelvic RT (external beam radiotherapy) - Radiation
Eligibility
18+
Male
What conditions do you have?
Select

Study Summary

This trial is testing a new cancer treatment for 100 patients with high-risk or node-positive prostate cancer. The treatment is a combination of radiotherapy and androgen deprivation therapy.

Eligible Conditions
  • Prostate Cancer

Treatment Effectiveness

Study Objectives

1 Primary · 7 Secondary · Reporting Duration: Baseline to 5-year follow-up

Baseline to 5-year Follow-up
Graded criteria based on CTCAE version 5.0 for acute genitourinary toxicity and late genitourinary and gastrointestinal toxicity
Measure of oncologic outcomes
Measure of onocologic outcomes
Measure the severity of lower urinary tract symptoms during the study
Overall survival
Patient-reported quality-of-life assessed by EPIC-26
Prostate cancer specific survival based on death from prostate cancer
Baseline to 5-year follow-up
Acute Grade >2 Gastrointestinal Toxicity

Trial Safety

Trial Design

1 Treatment Group

Moderate Hypofracitonated Boost to the Prostate with Pelvic Radiation Therapy
1 of 1

Experimental Treatment

100 Total Participants · 1 Treatment Group

Primary Treatment: Moderate hypofractionated boost to the prostate with pelvic RT (external beam radiotherapy) · No Placebo Group · N/A

Moderate Hypofracitonated Boost to the Prostate with Pelvic Radiation Therapy
Radiation
Experimental Group · 1 Intervention: Moderate hypofractionated boost to the prostate with pelvic RT (external beam radiotherapy) · Intervention Types: Radiation

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to 5-year follow-up

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,386 Previous Clinical Trials
471,869 Total Patients Enrolled
62 Trials studying Prostate Cancer
15,272 Patients Enrolled for Prostate Cancer

Eligibility Criteria

Age 18+ · Male Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

How many individuals are currently engaged in this medical experiment?

"Indeed, clinicaltrials.gov data shows that this investigation is actively recruiting patients after its initial posting on July 18th 2022 and latest update on the same day. The research requires 100 participants to be recruited from 1 site." - Anonymous Online Contributor

Unverified Answer

Is enrollment available in this clinical trial at the present time?

"According to the records on clinicaltrials.gov, this trial is open for enrolment. The study was initially made available on July 18th 2022 and has since been updated as of that same date." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.